Literature DB >> 30852524

Endovascular therapy for middle cerebral artery M2 segment occlusion: subanalyses of RESCUE-Japan Registry 2.

Masatomo Miura1,2,3, Shinichi Yoshimura1, Nobuyuki Sakai4, Hiroshi Yamagami5, Kazutaka Uchida1,6, Yoichiro Nagao1,3, Takeshi Morimoto6.   

Abstract

OBJECTIVE: To compare the efficacy of endovascular therapy (EVT) with that of medical treatment in 'real-world 'patients with M2 occlusion.
METHODS: This was a post hoc analysis of the Recovery by Endovascular Salvage for Cerebral Ultra-acute Embolism Japan Registry 2. Among 2420 patients in the registry, we evaluated patients with isolated M2 occlusion and those with functional independence before the stroke. Multivariable logistic regression analysis was used to evaluate and compare clinical outcomes between EVT and medical treatment. Additional propensity score-matched (PSM) analyses were performed. We performed subgroup analyses of the primary outcome (modified Rankin Scale score 0-2 at 90 days) using forest plots of treatment effects.
RESULTS: Overall, 372 patients with M2 occlusion (n=184 EVT; n=188, medical treatment) were evaluated. The EVT group had a higher baseline National Institutes of Health Stroke Scale score (median (IQR), 15 [9-19] vs 10 [5-16]) and earlier onset to hospital door time (110 [50-258] vs 150 [60-343] min) than the medical treatment group. After adjustment, EVT was significantly associated with higher odds of primary outcome (adjusted OR=2.09; 95% CI 1.26 to 3.47) and lower odds of mortality at 90 days (adjusted OR= 0.27; 95% CI 0.08 to 0.93). After PSM analyses (184 patients were 1:1 matched with each group), EVT was effective and safe relative to medical treatment. Effects favoring EVT were present in several subgroups of interest.
CONCLUSION: In patients with M2 occlusion, our registry suggests that EVT is effective and safe. © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  Endovascular therapy; middle cerebral artery occlusion; stroke; thrombectomy

Mesh:

Year:  2019        PMID: 30852524     DOI: 10.1136/neurintsurg-2018-014627

Source DB:  PubMed          Journal:  J Neurointerv Surg        ISSN: 1759-8478            Impact factor:   5.836


  6 in total

1.  Thrombectomy for M2 occlusions and the role of the dominant branch.

Authors:  Luís Henrique de Castro Afonso; Guilherme Borghini Pazuello; Guilherme Seizem Nakiri; Lucas Moretti Monsignore; Francisco Antunes Dias; Octávio Marques Pontes-Neto; Daniel Giansante Abud
Journal:  Interv Neuroradiol       Date:  2019-05-14       Impact factor: 1.610

2.  Predictors and Impact of Sulcal SAH after Mechanical Thrombectomy in Patients with Isolated M2 Occlusion.

Authors:  D Y Kim; S H Baik; C Jung; J Y Kim; S-G Han; B J Kim; J Kang; H-J Bae; J H Kim
Journal:  AJNR Am J Neuroradiol       Date:  2022-07-28       Impact factor: 4.966

3.  Association between oppositional defiant disorder and parenting style in children with attention deficit hyperactivity disorder.

Authors:  Cong Kou; Zhao-Min Wu; Juan Liu; Xiao-Lan Cao; Bin-Rang Yang
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2022-08-15

Review 4.  Efficacy and safety of mechanical thrombectomy for M2 segment of middle cerebral artery: a systematic review and meta-analysis.

Authors:  Jian Wang; Jiacheng Qian; Lu Fan; Yujie Wang
Journal:  J Neurol       Date:  2020-01-22       Impact factor: 4.849

5.  3D Turbo Spin-echo MRI-based Mechanical Thrombectomy at Middle Cerebral Artery Bifurcations.

Authors:  Jiro Ohara; Motoaki Fujimoto; Shoichi Tani; Hideki Ogata; Kampei Shimizu; Tomoaki Taguchi; Masahiko Itani; Yoshinori Akiyama
Journal:  Neurol Med Chir (Tokyo)       Date:  2021-12-08       Impact factor: 1.742

6.  Benefit of endovascular thrombectomy for M2 middle cerebral artery occlusion in the ARISE II study.

Authors:  Adam de Havenon; Ana Paula Narata; Aymeric Amelot; Jeffrey L Saver; Hormozd Bozorgchami; Heinrich Paul Mattle; Marc Ribo; Tommy Andersson; Osama O Zaidat
Journal:  J Neurointerv Surg       Date:  2020-11-20       Impact factor: 5.836

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.